Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Christopher, Tsu"'
Autor:
Joe Bolen, Mark Rolfe, Mark Manfredi, Li Yu, Paul Fleming, Larry Dick, Christopher Tsu, Khristofer Garcia, Jonathan Blank, Jane Liu, Frank Bruzzese, Paul Hales, Yu Yang, Jie Yu, Allison Berger, Michael Fitzgerald, Bret Bannerman, Yueying Cao, Edmund C. Lee, Erik Kupperman
The proteasome was validated as an oncology target following the clinical success of VELCADE (bortezomib) for injection for the treatment of multiple myeloma and recurring mantle cell lymphoma. Consequently, severalgroups are pursuing the development
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::01d07dcfcf19a153c02b55def60b337b
https://doi.org/10.1158/0008-5472.c.6500702
https://doi.org/10.1158/0008-5472.c.6500702
Autor:
Joe Bolen, Mark Rolfe, Mark Manfredi, Li Yu, Paul Fleming, Larry Dick, Christopher Tsu, Khristofer Garcia, Jonathan Blank, Jane Liu, Frank Bruzzese, Paul Hales, Yu Yang, Jie Yu, Allison Berger, Michael Fitzgerald, Bret Bannerman, Yueying Cao, Edmund C. Lee, Erik Kupperman
Supplementary Data, Figure Legends 1-3 from Evaluation of the Proteasome Inhibitor MLN9708 in Preclinical Models of Human Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::047537a2a69c0cda17d48c1520f0a30d
https://doi.org/10.1158/0008-5472.22383908
https://doi.org/10.1158/0008-5472.22383908
Autor:
Joe Bolen, Mark Rolfe, Mark Manfredi, Li Yu, Paul Fleming, Larry Dick, Christopher Tsu, Khristofer Garcia, Jonathan Blank, Jane Liu, Frank Bruzzese, Paul Hales, Yu Yang, Jie Yu, Allison Berger, Michael Fitzgerald, Bret Bannerman, Yueying Cao, Edmund C. Lee, Erik Kupperman
Supplementary Figure 3 from Evaluation of the Proteasome Inhibitor MLN9708 in Preclinical Models of Human Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::167a752aed7cf54345175b4a7222531b
https://doi.org/10.1158/0008-5472.22383899.v1
https://doi.org/10.1158/0008-5472.22383899.v1
Autor:
Joe Bolen, Mark Rolfe, Mark Manfredi, Li Yu, Paul Fleming, Larry Dick, Christopher Tsu, Khristofer Garcia, Jonathan Blank, Jane Liu, Frank Bruzzese, Paul Hales, Yu Yang, Jie Yu, Allison Berger, Michael Fitzgerald, Bret Bannerman, Yueying Cao, Edmund C. Lee, Erik Kupperman
Supplementary Figure 1 from Evaluation of the Proteasome Inhibitor MLN9708 in Preclinical Models of Human Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::35b97042635affb441b3a3b3d21b28b2
https://doi.org/10.1158/0008-5472.22383905.v1
https://doi.org/10.1158/0008-5472.22383905.v1
Autor:
Joe Bolen, Mark Rolfe, Mark Manfredi, Li Yu, Paul Fleming, Larry Dick, Christopher Tsu, Khristofer Garcia, Jonathan Blank, Jane Liu, Frank Bruzzese, Paul Hales, Yu Yang, Jie Yu, Allison Berger, Michael Fitzgerald, Bret Bannerman, Yueying Cao, Edmund C. Lee, Erik Kupperman
Supplementary Figure 2 from Evaluation of the Proteasome Inhibitor MLN9708 in Preclinical Models of Human Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15517bdacedd9fc09e61f244c92924e5
https://doi.org/10.1158/0008-5472.22383902.v1
https://doi.org/10.1158/0008-5472.22383902.v1
Autor:
Andrew Leis, Michael D. W. Griffin, Tuo Yang, David L. Gillett, Lawrence R. Dick, Michael J. Kuiper, Natalie J. Spillman, Christopher Tsu, Wilson Wong, Michael W. Parker, Craig J. Morton, Stanley C. Xie, Eric Hanssen, Riley D. Metcalfe, Leann Tilley
Publikováno v:
Nature Microbiology. 4:1990-2000
The activity of the proteasome 20S catalytic core is regulated by protein complexes that bind to one or both ends. The PA28 regulator stimulates 20S proteasome peptidase activity in vitro, but its role in vivo remains unclear. Here, we show that gene
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea9535c01f9c05493f2591dff6108398
https://doi.org/10.1038/s41564-019-0524-4
https://doi.org/10.1038/s41564-019-0524-4
Autor:
Paul Hales, Joseph J. Senn, Francis S. Wolenski, Christopher Tsu, Fleming Paul E, V Kadambi, Larry Dick, Jiejin Chen, Pooja Shah, Vilmos Csizmadia, Jingya Ma
Publikováno v:
Toxicology Research. 5:1619-1628
The proteasome inhibitor bortezomib is associated with the development of peripheral neuropathy in patients, but the mechanism by which bortezomib can induce peripheral neuropathy is not fully understood. One study suggested that off-target inhibitio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0173538061f7b4bc95eb0e11866e5f99
https://doi.org/10.1039/c6tx00220j
https://doi.org/10.1039/c6tx00220j
Autor:
Stanley C, Xie, David L, Gillett, Natalie J, Spillman, Christopher, Tsu, Madeline R, Luth, Sabine, Ottilie, Sandra, Duffy, Alexandra E, Gould, Paul, Hales, Benjamin A, Seager, Carlie L, Charron, Frank, Bruzzese, Xiaofeng, Yang, Xiansi, Zhao, Shih-Chung, Huang, Craig A, Hutton, Jeremy N, Burrows, Elizabeth A, Winzeler, Vicky M, Avery, Lawrence R, Dick, Leann, Tilley
Publikováno v:
Journal of Medicinal Chemistry
The Plasmodium proteasome represents a potential antimalarial drug target for compounds with activity against multiple life cycle stages. We screened a library of human proteasome inhibitors (peptidyl boronic acids) and compared activities against pu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::baa6b25d4621602ea8b6561b2d264873
https://pubmed.ncbi.nlm.nih.gov/30373366
https://pubmed.ncbi.nlm.nih.gov/30373366
Autor:
Claire L Langrish, Marcus Groettrup, Christian Schmidt, Michelle M Lindstrom, Timothy D. Owens, Christopher J. Kirk, J. Michael Bradshaw, Michael Basler, Jacob LaStant, Elmer Maurits, Christopher Tsu, Herman S. Overkleeft
Publikováno v:
EMBO reports. 19(12)
Cells of hematopoietic origin express high levels of the immunoproteasome, a cytokine-inducible proteasome variant comprising the proteolytic subunits LMP2 (β1i), MECL-1 (β2i), and LMP7 (β5i). Targeting the immunoproteasome in pre-clinical models
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4207e7827a057b13f7e795c9fae3f39f
https://pubmed.ncbi.nlm.nih.gov/30279279
https://pubmed.ncbi.nlm.nih.gov/30279279
Autor:
Cynthia Barrett, Alexandra E. Gould, Janice Chin, Mable Brunson, John Ringeling, Christopher Tsu, R. Scott Rowland, Krista Wager, Kara Hoar, Juan Gutierrez, He Xu, Dylan England, Kris Garcia, Christopher Blackburn, Kenneth Gigstad
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 24:5450-5454
Acyl derivatives of 4-(aminomethyl)-N-hydroxybenzamide are potent sub-type selective HDAC6 inhibitors. Constrained heterocyclic analogs based on 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine show further enhanced HDAC6 selectivity and inhibitory activity
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76984e37b68c0abc013438b7f50f96ec
https://doi.org/10.1016/j.bmcl.2014.10.022
https://doi.org/10.1016/j.bmcl.2014.10.022